Peter MacCallum Cancer Centre at ASH 2026
Dec 12–15, 2026 New Orleans, LA ~30k attendees Website
Peter MacCallum Cancer Centre brings 8 presentations to ASH 2026 in New Orleans. Its program centres on lymphoma, CAR T-cell therapy and acute myeloid leukemia. It includes circulating tumour DNA tracking through CAR-T and a session on resistance to BCL2 inhibitors.
| Organization | ASH 2026 Attendance |
|---|---|
Peter MacCallum Cancer Centre Melbourne, Australia | |
Public cancer hospital and research centre in Melbourne, Australia. | Symposium Fri Dec 11 7:00am–10:00am Current Management Paradigms in Acute Myeloid Leukemia – A Second Opinion Case Review Difficult acute myeloid leukemia cases where doctors sought second opinions, paired with reviews of recent data, current management, and ongoing trials. Session Fri Dec 11 3:00pm–3:02pm Session Fri Dec 11 3:00pm–6:00pm Scientific Workshop on Germline Predisposition to Hematopoietic Malignancies and Bone Marrow Failure Inherited risk for blood cancers and marrow failure: disease mechanisms, gene-based medicines, and how to monitor people at risk. Talk Fri Dec 11 3:05pm–4:00pm Session Fri Dec 11 4:33pm–5:15pm Novel Insights in Diagnostics and Molecular Surveillance High-sensitivity sequencing and clone tracking to monitor people who carry inherited variants that predispose them to blood cancer. Symposium Fri Dec 11 7:00pm–10:00pm Advancing the DLBCL Paradigm: Sequencing Bispecifics in Optimizing Patient Care Where bispecific antibodies fit in diffuse large B-cell lymphoma, weighed against CAR-T by patient fitness, access, and T-cell health. Oral Sat Dec 12 9:30am–11:00am Poster Sat Dec 12 5:30pm–7:30pm Poster Sat Dec 12 5:30pm–7:30pm Poster Sat Dec 12 5:30pm–7:30pm Oral Sun Dec 13 12:00pm–1:30pm Oral Sun Dec 13 4:30pm–6:00pm |
Find decision makers at Peter MacCallum Cancer Centre
Tell us what you sell and we’ll find the people at Peter MacCallum Cancer Centre most likely to buy it.
- Who to contact
- Their contact info
- What to say
- Free, no sign-up
Not affiliated with or endorsed by the American Society of Hematology (ASH). Submit a correction